Title : Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.

Pub. Date : 2004 Mar 1

PMID : 14967461






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2). Lapatinib epidermal growth factor receptor Homo sapiens